BRAVO: Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

Sponsor

Anna Raciborska (Other)

Overall Status

Recruiting

CT.gov ID

NCT04943198

Collaborator

Maria Sklodowska-Curie National Research Institute of Oncology (Other), Łukasiewicz Research Network (Other), Wrocław University of Environmental and Life Sciences (Other)

Enrollment

Location

Arms

62.7

Anticipated Duration (Months)

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Prospective, interventional, open, randomized, single-center, non-commercial clinical trial to optimize treatment and dosage of vemurafenib in juvenile patients with histiocytosis resistant to conventional therapy and in whom the BRAF gene mutation has been found.

Condition or Disease	Intervention/Treatment	Phase
Histiocytosis	Drug: Vemurafenib	Phase 2

Detailed Description

BRAVO clinical study is part of the POLHISTIO project. The POLHISTIO project is a non-commercial clinical trial aimed at optimizing the diagnosis and treatment of juvenile patients with histiocytosis. The project objectives are defined as follows: 1) to estimate the nature and frequency of mutations in patients with histiocytosis in both tumor tissues and free-circulating DNA; 2) to compare molecular test results with clinical data; 3) to evaluate the diagnostic usefulness of the status of molecular analysis (MRD) as a prognostic factor compared with other recognized factors; 4) in the case of failure of conventional therapy - to modify treatment and to apply targeted treatment, based on molecular status of gene mutation. The project is intended to include patients from all over Poland.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

25 participants

Allocation:

Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

Actual Study Start Date :

Apr 1, 2021

Anticipated Primary Completion Date :

Mar 30, 2026

Anticipated Study Completion Date :

Jun 23, 2026

Arms and Interventions

Arm	Intervention/Treatment
Experimental: R1 time of vemurafenib treatment vemurafenib will be given to 6 months after BRAF negativization	Drug: Vemurafenib 20 mg/kg/day
Experimental: R2 time of vemurafenib treatment vemurafenib will be given to 12 months after BRAF negativization	Drug: Vemurafenib 20 mg/kg/day

Arm

Intervention/Treatment

Experimental: R1 time of vemurafenib treatment

vemurafenib will be given to 6 months after BRAF negativization

Drug: Vemurafenib

20 mg/kg/day

Experimental: R2 time of vemurafenib treatment

vemurafenib will be given to 12 months after BRAF negativization

Drug: Vemurafenib

20 mg/kg/day

Outcome Measures

Primary Outcome Measures

event-free survival [2 years]
Event-free survival (EFS) was defined as the time interval from the date of diagnosis to the date of disease progression, recurrence, second malignancy, death or to date of last follow-up for patients without events.

Secondary Outcome Measures

Molecular relapse (in ct DNA) [2 years]
Molecular relapse was defined as the time interval from the date of BRAF negativization to the date of positive results of BRAF mutation
Time to negative mutation test results (in ct DNA) [2 years]
Time to negative mutation test results (in ct DNA) was defined as the time interval from the date of positive BRAF mutation to the date of negative results of BRAF mutation

Eligibility Criteria

Criteria

Ages Eligible for Study:

0 Years to 18 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

The presence of mutations in the BRAF gene in tumor tissues and/or in circulating tumor DNA (ctDNA) at any stage of treatment or follow-up.
Failure of the treatment (at least one of below needs to apply in order for this requirement to be satisfied):

Progression on the I and II line treatment, and involving of a minimum one risk organ; previous treatment should include a minimum of 6 weeks of weekly Vinblastine with a minimum of 28 days prednisolone or minimum 2 cycles of Cytosine Arabinoside in 4-day cycles and/or Cladribine in 5-day cycles as a treatment of 2 line, or
Disease reactivation after an initial response to treatment with Vinblastine and prednisolone as the first line and no response to treatment of the second line using a minimum of 2 cycles of one of two drugs: Cytosine Arabinoside in 4-day cycles and/or Cladribine in 5-day cycles as a treatment of 2 line and the involving of a minimum one risk organ, or
Third or subsequent reactivation of disease with or without risk organ involvement, or
Reactivation of disease after Vemurafenib therapy has been completed, or
The appearance of signs of neurodegenerative disorder (ND) in MRI of the central nervous system (CNS).

Signing of informed consent for trial participation (including for Vemurafenib treatment) according with current legal regulations.
Consent to the use of effective contraception throughout the Vemurafenib administration period and a minimum of 1 year after discontinuation in patients at puberty and sexual maturity.
Participation in HISTIOGEN trial.

Exclusion Criteria:

Lack of inclusion criteria.
Pregnancy and breastfeeding .
Hypersensitivity to the study drug or any of its ingredients.
Iritis, uveitis, obstruction of the retinal veins.
Simultaneous treatment with other drugs which might interact with Vemurafenib.
Persistent toxicity related to prior therapy, making it impossible to treat with Vemurafenib.
Diagnosis of other malignancies before study inclusion.
Other acute or persistent disorders, behaviors or abnormal laboratory test results, which might increase the risk related to the participation in this clinical trial or to taking the study drug, or which might influence the interpretation of the study results, or which, in the investigator's opinion, disqualify a patient from participating in the trial.